Dale Pfost 163 connections

Board of Directors , Multiple (see below)

Professional Summary

Dale Pfost is a biotechnology and high-technology entrepreneur. He was the founding CEO of four successful companies, two of which achieved peak market capitalizations of $2 billion. His experience includes raising $330 million in a total of 19 public and private financings. The companies he has founded include: Acuity Pharmaceuticals (in 2007, merged into public company Opko Health, AMEX: OPK); Orchid BioSciences (IPO in 2000, NASDAQ: ORCH); Oxford GlycoSciences (IPO 1998); and Infinitek, which developed the Biomek 1000 (acquired by SmithKline Beckman in 1984). He has a Ph.D. in Solid State Physics from Brown University and a BS in Physics from UCSB. He is a private pilot with an instrument rating.

Contact Info

(work)

Phone

6094687834 (work mobile)

2155425973 (work)

2155425974 (work fax)

Address

1525 Bardsey Lane
Ambler, PA 19002 (work)

Work/Education

Work Experience

Multiple (see below) / Board of Directors

2008 - Present

Sunstones BioSciences, Mitergy Pharmaceuticals, Smart Genetics, Biopticon.

Open for full time CEO positions.

Relocating to SF Bay Area and New Orleans.

Acuity Pharmaceuticals, Inc. / CEO and Chairman

2003 - 2007

Acuity was an ophthalmology pharmaceutical company with first-ever clinically-tested drug based on siRNA. Lead drug now in phase 3 clinical trials for wet AMD. In 2007, merged company into OPKO a company led by successful financier and entrepreneur, Phil Frost. Opko is listed on AMEX: OPK.

Orchid BioSciences / CEO and Chairman

1996 - 2002

Spint-out of Sarnoff with micro-fluidics technology and became the leading DNA testing company through acquisitions. IPO 2000 on NASDAQ: ORCH). Grew to approximately $65 million with seven laboratories worldwide, processing close to one million tests per year. Leading SNP company with early stage personalized medicine business based on pharmacogenetics.

Oxford GlycoSciences, Ltd. (OGS) / CEO

1988 - 1996

Leading glycobiology company. Developed world's first complex carbohydrate sequencer. Developed significant proteomics program. Transformed company into emerging biotechnology company. IPO 1998.

SmithKline Beckman -- Beckman / General Manager, Director of Robotics and Automated Chemistry Systems

1984 - 1988

Grew Biomek business and added molecular biology instruments, including automated systems for the front-end of DNA sequencing. A leading company in high-throughput screening and flexible ELISA systems.

Infinitek, Inc. / President

1982 - 1984

Developed Biomek 1000, a leading laboratory automation system. Sold company to SmithKline Beckman--Beckman's Spinco Division in 1984 and became the General Manager of the business unit.